Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMNIMARA Trial
2024-519935-41-00Phase 3Authorised
- Sponsor
- Antwerp University Hospital
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of somatropin and letrozole in growth disorder (2 arms), sponsored by Antwerp University Hospital. Primary endpoint: Adult height gain. Planned start Jan 2025; status: authorised.
02
Drugs
somatropinletrozole
03
Conditions
growth disorder
Beyond the preview
Go deeper on 2024-519935-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519935-41-00.